Theaflavin-3,3'-digallate triggers apoptosis in osteosarcoma cells via the caspase pathway
Yat-Yin Law1,2,3, Yi-Hsien Hsieh1,4, Yih-Shou Hsieh2
1Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Abstract:
Osteosarcoma is a cancer associated with a guarded prognosis. Various compounds can induce apoptosis in osteosarcoma cells. Theaflavin-3,3'-digallate (TF3) has been demonstrated to alter cell growth and induce apoptosis in various cancer cells. The present study investigated the apoptotic effect of TF3 on osteosarcoma cells. It further explored key apoptotic pathways activated by TF3. Viability of 143B and U2OS osteosarcoma cells after TF3 treatment was assessed. The effects of TF3 on key apoptotic pathways were analyzed. Furthermore, a xenograft mouse model of osteosarcoma was established for in vivo experiments. The results indicated that TF3 significantly reduced the viability of 143B and U2OS cells. Western blotting revealed that TF3 upregulated the expression of cleaved caspase-3 and cleaved caspase-9 in osteosarcoma cells. In addition, TF3 increased the levels of phosphorylated histone H2Ax, Bax, Bak1, and cytochrome c, while reducing the levels of Mcl-1 and survivin in osteosarcoma cells. Furthermore, TF3 significantly reduced the average tumor volume in the xenograft model. Overall, this study suggests that TF3 induces apoptosis in osteosarcoma cells, primarily by regulating the caspase pathway.
Insights
Theaflavin-3,3-digallate (TF3) effectively reduces osteosarcoma cell viability and tumor growth. TF3 triggers apoptosis by activating the caspase pathway and modulating key proteins involved in cell death.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma presents a significant clinical challenge with limited treatment options.
- Inducing apoptosis in cancer cells is a key therapeutic strategy.
- Theaflavin-3,3-digallate (TF3), a compound from tea, shows potential anti-cancer effects.
Purpose of the Study:
- To investigate the apoptotic effects of TF3 on osteosarcoma cells.
- To elucidate the molecular pathways through which TF3 induces apoptosis.
- To evaluate TF3's efficacy in an in vivo osteosarcoma model.
Main Methods:
- Cell viability assays (MTT) on 143B and U2OS osteosarcoma cell lines.
- Western blot analysis to assess protein expression changes.
- Establishment of an osteosarcoma xenograft mouse model for in vivo studies.
Main Results:
- TF3 significantly decreased osteosarcoma cell viability.
- TF3 upregulated cleaved caspase-3 and caspase-9, indicating caspase pathway activation.
- TF3 modulated pro-apoptotic (Bax, Bak1) and anti-apoptotic (Mcl-1, survivin) proteins, and increased DNA damage marker (H2Ax).
- TF3 treatment led to a significant reduction in tumor volume in the xenograft model.
Conclusions:
- TF3 effectively induces apoptosis in osteosarcoma cells through the intrinsic caspase pathway.
- TF3 demonstrates therapeutic potential for osteosarcoma treatment.
- Further research into TF3 as an anti-osteosarcoma agent is warranted.
Related Concept Videos
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Apoptosis
Caspases
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...


